Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease
1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with...
Gastroenterology
Reports of high-impact gastroenterology studies by medical professionals
Randomized Phase III trial of Ramucirumab finds benefit for patients with refractory advanced gastric cancer
1. The addition of ramucirumab to irinotecan in patients with ramucirumab-refractory advanced or recurrent gastric or gastroesophageal cancer (AGC) did...
Obesity is a mediating factor for gallstone disease risk
1. In a retrospective cohort study of adults included in the National Health and Nutrition Examination Survey (NHANES), obesity was...
Prophylactic vancomycin may reduce recurrent Clostridioides difficile infection but increases antimicrobial resistance
1. In this randomized clinical trial, oral vancomycin reduced the risk of recurrent Clostridioides difficile infection (CDI) in participants with...
Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
1. In patients with pouchitis associated with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC), the use of oral...
Structured exercise intervention improves survival in colon cancer patients
1. In this randomized controlled trial, patients with resected stage III or high-risk stage II colon cancer who completed adjuvant...
Fecal calprotectin is a useful marker for defining small bowel endoscopic remission in Crohn’s disease
1. In patients with Crohn’s disease (CD), fecal calprotectin (FC) was a useful biomarker for monitoring small bowel lesions and...
Time-restricted eating does not confer changes in sleep, mood, or quality of life
1. Time-restricted eating, regardless of timing of the eating window, did not result in significant changes in sleep, mood, or...
Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
1. In this series of target trial emulations, several common medications were not found to significantly affect the risk of...
Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis
1. Use of Sodium-Glucose Cotransporter 2 (SGLT-2) inhibitors among adults with cirrhosis receiving diuretic therapy was associated with lower incidence...
